BioSpace News Archive

Genetown

Editas Medicine to Participate in Upcoming Investor Conferences - January 31, 2024

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upcoming investor conferences.

January 31, 2024
·
1 min read
Pharm Country

Centinel Spine® Record prodisc® Total Disc Replacement Growth of 55% in 2023 Sets the Foundation for Continued Growth in 2024 and Beyond

Centinel Spine®, LLC announced achievement of record full-year 2023 TDR business results, setting the stage for continued accelerated growth in 2024.

January 31, 2024
·
6 min read
FDA

Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate VTR-297 for the treatment of onychomycosis.

January 31, 2024
·
4 min read
Biotech Beach

Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference

AnaptysBio, Inc. today announced that Daniel Faga, president and chief executive officer, will present at Guggenheim’s 6th Annual Biotechnology Conference.

January 31, 2024
·
1 min read
BioCapital

European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®

CEL-SCI Corporation (NYSE American: CVM) today announced that the European Medicines Agency (EMA) Paediatric Committee granted CEL-SCI a product-specific waiver of strict requirements for commercialization of cancer drugs in the European Union (EU).

January 31, 2024
·
12 min read
Business

Trialbee and Massive Bio Join Forces to Improve Clinical Trial Access and Patient Recruitment for Oncology and Hematology

Trialbee, your global patient recruitment and enrollment solution, today announced its Omnichannel Network partnership with Massive Bio, a global leader in AI enabled patient journey mapping platform, to help better connect cancer patients and their oncologists/hematologists to clinical trials.

January 31, 2024
·
5 min read
Lone Star Bio

AustinPx Partners with Microsize on KinetiSol® Technology

AustinPx and Microsize announced the strategic partnership to accelerate the commercial application of AustinPx’s KinetiSol® Technology platform.

January 31, 2024
·
3 min read
Deals

Corbus Pharmaceuticals Announces Pricing of Public Offering

Corbus Pharmaceuticals Holdings, Inc. today announced the pricing of an underwritten public offering of 4,325,000 shares of its common stock at a public offering price of $19.00 per share.

January 31, 2024
·
3 min read
Deals

FibroBiologics Announces Direct Listing on NASDAQ Under the Stock Ticker FBLG

FibroBiologics, Inc. announced that trading of the FibroBiologics stock commenced today on Nasdaq under the stock ticker FBLG.

January 31, 2024
·
3 min read
Pharm Country

BioSig Announces Reverse Stock SplitCommon Stock Will Begin Trading on Split-Adjusted Basis on February 2, 2024

BioSig Technologies, Inc., a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares.

January 31, 2024
·
5 min read